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Cytokines are secreted proteins that regulate many as- 
pects of cellular growth, differentiation, activation, and ef- 
fector function, and play an important role in immune and 
inflammatory responses. The binding of cytokine iigands 
to members of the cytokine receptor superfamily typically 
results in receptor homo- or heterodimerization, and trig- 
gering of intracellular signals. One of the earliest signaling 
events is the activation of protein tyrosine kinases (PTKs), 
such as members of the Src or Janus kinase (Jak) families, 
which are physically associated with the receptor (Tani- 
guchi, 1995). Kinase activation likely occurs via transphos- 
phorylation by kinases associated with receptor compo- 
nents that have been brought into close proximity by binding 
of ligand. After activation, receptor-associated PTKs phos- 
phoryiate several substrates critical for signal transduction, 
including specific tyrosine residues in the cytoplasmic do- 
mains of the receptors. 
One important component of cytokine signaling is spe- 
cific transcriptional activation of target genes, which is 
rapid and does not require the synthesis of new proteins. 
Analysis of rapid transduction of signals to the nucleus 
has led to the identification and characterization of the Jak- 
signal transducer and activator of transcription (STAT) sig 
naling pathway (Schindler et al., 1992; Muller et al., 1993; 
reviewed by Darnell et al., 1994; lhle et al., 1994). STAT 
factors are rapidly tyrosine-phosphorylated after stimula- 
tion with cytokines, and subsequently dimerize and trans- 
locate to the nucleus, where they can activate transcrip- 
tion. To date, six members of the STAT family, Stat1 
through Stat6, have been identified and characterized. 
STATS are widely expressed in different cell types and 
tissues, except for Stat4, which is expressed predomi- 
nantly in testis and in cells of hematopoietic origin. 
A large number of cytokines, growth factors, and the 
interferons (IFNs) activate the Jak-STAT intracellular sig- 
naling pathway (Shuai et al., 1992; Larner et al., 1993; 
Lutticken et al., 1994; Hou et al., 1994, 1995; Rothman 
etal.,1994;Linetal.,1995;Szaboetal.,1995;Greenlund 
et al., 1995; see Table 1). Typically, stimulation by a partic- 
ular cytokine results in the activation of a distinct pair of two 
of the four known Jak kinases. Jak kinases are required 
for tyrosine phosphorylation and activation of STATS, al- 
though it is not yet clear whether Jaks phosphorylate 
STATS directly. Tyrosine phosphorylation and activation 
of STATS leads to transcriptional activation of unique, but 
overlapping, patterns of target genes, which characterize 
specific cellular responses to cytokines and extracellular 
stimuli. 
An important challenge in cytokine biology is under- 
standing how more than twenty distinct extracellular li- 
gands can achieve signaling specificity through activation 
of relatively small families of Jak kinases and STAT tran- 
scription factors. Specificity may be achieved, in part, 
through relatively selective activation of individual STATS 
‘by cytokines (Table 1). The selective pattern of STAT acti- 
vation raises several important questions. What is the mo- 
lecular mechanism by which STATS are selectively acti- 
vated? How do particular STATS activate unique patterns 
of gene expression? And, how can cytokines that activate 
the same STATS (such as interieukin6 [IL-61 and IL-lo; 
Table 1) induce specific genes and cellular responses? 
Work published over the past several months, including 
several papers in Immunity, provides some of the answers 
to these questions. 
Selective Recruitment of STATS 
to Cytokine Receptors 
Detection of tyrosine-phosphorylated activated STATS in 
the cytoplasm prior to translocation to the nucleus, activa- 
tion of Stat1 in enriched membrane preparations, and 
coimmunoprecipitation of Stat3 with gp130 (a signaling 
molecule that is part of the receptors for several cytokines, 
including IL-6) suggested that STATS are recruited into a 
receptor-associated signaling complex during the activa- 
tion process, and likely are phosphorylated by receptor- 
associated Jaks (Igarashi et al., 1993; Lutticken et al., 
1994; Darnell et al., 1994). Selectivity of STAT activation 
could be determined by specific docking of STATS with 
proteins in the receptor complex, or by specific phosphory- 
lation of STAT substrates by receptor-associated kinases. 
A specific docking interaction between STATS and intra- 
cellular cytokine receptor sequences containing tyrosine 
residues (which are phosphorylated after ligand binding) 
was proposed on the basis of experiments using peptides 
derived from the IFNy, IL-4, IL-2 (6 subunit), and IL-7 recep- 
tors (Greenlund et al., 1994; Hou et al., 1994; Lin et al., 
1995). A tyrosine-phosphorylated, but not unphosphory- 
lated, nonapeptide derived from an IFNy receptor (IFNyR) 
sequence containing a functionally important tyrosine resi- 
Table I. Activation of Jak Kinases and STATS by Extracellular 
Ligands 
Receptor Activated Jaks Activated STATS 
IFNa Jakl, TykP Statl, StatP, Stat3 
IFNy Jakl, JakP Stat1 
IL-2 Jakl, Jak3 Stat3,’ Stat5 
IL-4 Jakl, Jak3 Stat6 
IL-6 Jakl, JakP, TykP Statl, Stat3 
IL-7 Jakl, Jak3 Stat5 
IL-IO Unknown Statl, Stat3 
IL-12 Jak2, TykP Stats, Stat4 
IL-13 Unknown Stat6 
IL-15 Unknown Stat5 
Prolactin JakP, ?Jakl Stat5 
The ligands shown have been selected (from more than twenty ligands 
that activate STATS) to emphasize the relative selectivity of STAT 
activation. 
a IL-2 activates Stat3 in preactivated, but not resting, peripheral blood 
mononuclear cells. 
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due inhibited Stat1 activation in crude cell extracts, and 
Stat1 coprecipitated with immobilized peptide. This inter- 
action was specific for Stat1 , which is activated by IFNy, 
and was not detected with Stat2, which is activated by 
IFNa. Furthermore, IL-4Rderived tyrosine phosphopep- 
tides inhibited DNA binding by the IL-4-induced Stat6, and 
IL-2R and IL-7R phosphopeptides specifically inhibited ac- 
tivation of Stat5 
Recent biochemical and molecular biologic experiments 
support and extend the hypothesis that STATS interact 
specifically with intracellular domains of cytokine recep- 
tors. Adirect and selective association of Stat1 with IFNyR- 
derived phosphopeptides, and Stat6 with ILQR-derived 
phosphopeptides has been demonstrated using purified 
Stat1 and Stat6 proteins. Unphosphorylated Stat1 bound 
to IFNyRderived phosphopeptides with dissociation equi- 
librium constants of 50 nM or 137 nM (Greenlund et al., 
1995; Schindler et al., 1995). Selectivity in STAT recogni- 
tion of receptor sequences was conferred by the region 
corresponding to the STAT SH2 domain, a conserved 
modular protein domain, which mediates protein-protein 
interactions and binds to phosphotyrosinecontaining se- 
quences (Schindler et al., 1995). STAT-receptor interac- 
tions have also been analyzed in cells that have been 
transfected with constructs encoding mutated and chime- 
ric receptors and STATS. A consensus sequence YXXQ 
present in gpl30 and LIF receptor cytoplasmic domains 
was shown to be necessary and sufficient for tyrosine- 
phosphorylation of Stat3 (Stahl et al., 1995). Conversely, 
specificity of a particular STAT for a receptor sequence 
was shown to reside in the SH2 domain, since a chimeric 
STAT wherein the Stat2 SH2 domain was replaced by 
the Stat1 SH2 domain exhibited selectivity for the IFNyR, 
which is characteristic of Stat1 , but not Stat2 (Heim et al., 
1995). 
Taken together, these results strongly support a model 
whereby selectivity of STAT activation is directed by a 
specific interaction between a STAT SH2 domain and a 
short receptor sequence, which contains a phosphory- 
lated tyrosine. Further fine-tuning of specificity may occur 
through interaction of STATS with other receptor-associated 
molecules, including previously recruited STATS or the 
Jak kinases (Heim et al., 1995; Greenlund et al., 1995; 
Guschin et al., 1995). However, the lack of correlation 
between activation of specific Jaks with related STATS 
(Table l), the results obtained using chimeric receptors 
and STATS, and also STATS containing mutations sur- 
rounding the phosphorylated tyrosine, suggest that the 
Jak kinases may be relatively nonspecific. This model also 
suggests a basis for redundancy in action of cytokines that 
do not share signaling subunits: the receptors may contain 
tyrosine residues surrounded by similar sequences, which 
are recognized by the same STAT (Lin et al., 1995; Stahl 
et al., 1995; Greenlund et al., 1995). After docking with 
the receptor, STATS become tyrosine-phosphorylated, 
dissociate from the receptor, and form dimers in a process 
that may be guided by the relative affinity of STAT SH2 
domains for various phosphotyrosinecontaining sequences 
(Greenlund et al., 1995). 
DNA Binding Speclflclty 
The most straightforward way to translate selectivity of 
STAT activation into selectivity of target gene activation 
would be through specific interactions of STATS with DNA 
sequences in promoters of different genes. Experiments 
using chimeric Statl-Stat3 and Statl-Stat6 proteins have 
localized the STAT DNA-binding domain to a region of 
approximately 110 aa immediately amino-terminal to the 
putative SH3 domain, and thus distinct from the SH2 re- 
gion, which determines specificity of interaction with re- 
ceptors (Horvath et al., 1995; Schindler et al., 1995). A 
systematic analysis of binding of induced STAT com- 
plexes to synthetic oligonucleotides, binding site selection 
using purified proteins, and analysis of binding specificity 
of chimeric STATS have been used to determine the extent 
of DNA binding specificity (Seidel et al., 1995; Schindler 
et al., 1995; see Table 2). 
STAT binding sequences can vary considerably from a 
consensus palindromic sequence lTCN~2_4,GAA, and can 
be divided into two groups: sequences that bind several 
different STAT complexes, and sequences that prefer- 
entially bind a particular STAT (Table 2). Conversely, a 
particular STAT complex can bind to several different se- 
quences, although the apparent affinity of binding is vari- 
able. Interestingly, discrimination among sequences was 
most prominent using purified proteins (presumably ho- 
modimers) and optimal sequences identified using binding 
site selection (Schindler et al., 1995). Spacing between 
the palindromic half-sites appears to be important in de- 
termining which STATS are able to bind (Table 2) although 
the spacer and flanking nucleotides also play a role. Tran- 
scriptional activation, by STATS, of reporter genes con- 
taining various binding sites generally, but not always, cor- 
related with DNA binding (Seidel et al., 1995). 
Table 2. Comparison of STAT-Binding Oligonucleotide Sequences 
Synthetic 
Jun 0 
Synthetic 
RF-1 
FcyRl 
Selectedb 
Synthetic 
CE 
SelectedD 
Core Sequence 
TTCNNGAA 
GTCAGGAA 
TTCNNNGAA 
TTCCCCGAA 
TTCTGGGAA 
TTCCCGGAA 
TTCNNNNGAA 
TTCCCAAGAA 
TTCGTGTGAA 
N STAT Binding 
Stat3 
Stat3 
Statl, Stat3, Stat5, Stat6 
Statl, Stat3, Stat5 Stat6 
Statl, Stat3,a Stat5 Stat6 
Stat1 
Stat6 
Stat6 
Stat6 
Synthetic, sequences synthesized to analyze the effects of spacing 
between the palindromic TTC and GAA half-sites; the spacer nucleo- 
tides (N) are variable and these sequences do not necessarily corre- 
spond to currently known promoter sequences. Selected, sequences 
identified using binding site selection with purified Stat1 or Stat6 pro- 
teins(Schindler et al., 1995). Stat2and Stat4 are not included because 
of incomplete information, and, in some cases, the binding of STATS 
has been inferred from the binding of complexes induced by particular 
cytokines (Seidel et al., 1995). 
a Stat3 binds relatively weakly to the FcyRl promoter site. 
D Binding of Stat1 and Stat6, but not Stat3 or Stat5 to these sequences 
was tested (Schindler et al., 1995). 
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This pattern of binding specificities suggests a frame- 
work for explaining overlapping patterns of genes that are 
induced by different cytokines. Promoters of genes that 
are induced by numerous cytokines, such as IRF-1, would 
contain sequences that bind many different STATS, 
whereas genes that are specifically induced by a particular 
cytokine, such as CE (Kotanides and Reich, 1993; Seidel 
et al., 1995) would contain a more restrictive binding site 
(Table 2). Furthermore, the existence of sequences that 
bind Stat1 (activated by IFNT) but not Stat6 (activated by 
IL+, and vice versa (Schindler et al., 1995) suggests that 
some of the opposing actions of these cytokines may be 
achieved through activation of distinct sets of effector 
genes. Further work is required to increase the under- 
standing of relationships between binding and transcrip- 
tional activation by STATS, and to address whether addi- 
tional specificity may be achieved through interactions of 
STATS with different proteins bound to adjacent promoter 
sequences, or with the general transcriptional machinery. 
Interaction wlth Additional Intracellular 
Signals and Proteins 
Many cytokines that activate STATS, for example IL-6 or 
epidermal growth factor, also activate intracellular serine 
kinases (Kishimoto et al., 1994). Stat1 and Stat3 can be 
phosphorylated in a regulated and inducible manner on 
serine residues, in addition to tyrosine residues @hang et 
al., 1995; Wen et al., 1995). lntracellularserinephosphory- 
lation can affect STATfunction, since addition of the serine 
kinase inhibitor H7, or of exogenous protein phosphatase 
2A, resulted in altered Stat3 DNA-binding activity (Zhang 
et al., 1995). Furthermore, a mutation that blocks Stat1 
serine phosphorylation, but does not affect tyrosine phos- 
phorylation or DNA binding, exhibited substantially de- 
creased ability to activate transcription (Wen et al., 1995). 
Thus, modification of STATS by additional signals trig- 
gered by a particular cytokine, or by additional ligands, 
can alter STAT function. This provides another level of 
regulation of STATS and may explain, at least in part, how 
cytokines that activate the same STATS may activate dif- 
ferent target genes and cellular responses. 
Another type of interaction may occur when an initial 
stimulus triggers cell activation or differentiation, with a 
resulting change in the pattern of STATS activated by a 
given ligand. For example, IL-2 activated Stat5 in resting 
peripheral blood mononuclear cells, but activated Stat3 
and a protein that is most likely a different isoform of Stat5 
in cells that had been preactivated with phytohemaggluti- 
nin (Lin et al., 1995). IL-3 activated different isoforms of 
Stat5 in immature and more differentiated myeloid cells 
(Azam et al., 1995). It islikely that cellactivationordifferen- 
tiation result in changes in expression of STATS, or 
changes in expression or composition of receptors, with 
a resulting change in the STATS that are activated by a 
particular cytokine. Additional levels of regulation of STAT 
activity include heterodimerization and interactions with 
additional proteins, such as p46, which alter DNA binding 
specificity (reviewed by Darnell et al., 1994). 
Negative Regulation of STAT Activity 
Negative regulation of STATS may occur by inhibition of 
upstream signaling events, or by deactivation of activated 
STATS. Evidence suggestive of negative regulation through 
several different mechanisms has been described. STAT 
DNA-binding activity typically disappears within several 
hours of stimulation, presumably through the action of pro- 
tein-tyrosine phosphatases (PTPs). Specific recruitment 
of PTPl D to the gp130 signaling molecule, and SH-PTPl 
to the erythropoietin receptor have been described and 
shown to be important functionally (Stahl et al., 1995; 
Klingmuller et al., 1995). Examples of blocking of signaling 
pathways upstream of STATS include inhibition of Stat1 
activation in monocytes by immunoglobulin G (IgG) im- 
mune complexes and inhibition of IL-12 signaling during 
differentiation of T cells along the Th2 pathway (Feldman 
et al., 1995; Szabo et al., 1995). In both cases, inhibition 
was associated with normal levels of receptor expression, 
but no detectable tyrosine phosphorylation of STATS or 
Jak kinases. These results suggest that noncytokine li- 
gands, which bind to different classes of receptors, may 
modulate STAT activity and specificity. 
Negative regulation of STATS may be particularly im- 
portant in a physiologic setting where cells are exposed 
to numerous stimuli simultaneously. Cells may respond 
selectively to only a subset of ligands present in the extra- 
cellular environment (Feldman et al., 1995; Szabo et al., 
1995; Sengupta et al., 1995), with a resulting apparent 
dominant effect of particular ligands. Alternatively, antago- 
nistic cytokines may not interfere with activation of STAT 
DNA binding by the opposing cytokine. For example, si- 
multaneous treatment of cells with IFNy and IL-4 results 
in the simultaneous activation of Stat1 and Stat6, which 
can bind to the same sequence in the FcTRl promoter 
(Larner et al., 1993; Kotanides and Reich, 1993; Schindler 
et al., 1994; Lehmann et al., 1994). The mechanism by 
which IL-4 inhibits the IFNy induction of this promoter is 
unknown, but may occur in the nucleus at the level of 
transcriptional activation. 
Conclusions 
Recent studies have documented the essential role of the 
Jak-STAT pathway in transducing signals from cytokine 
receptors to the nucleus. Dramatic progress has been 
made in understanding how a cytokine specifically acti- 
vates a particular STAT, and how the STAT may then se- 
lectively bind to sequences present in different gene pro- 
moters. Selective activation of STATS by cytokines is 
guided by interactions of STAT SH2 domains and tyrosine- 
phosphotylated receptor sequences. The role of the STAT 
SH3 domain and of possible interactions with additional 
proteins in the receptor complex is not known, and it is not 
yet clear whether STATS can couple to different classes of 
receptors, possibly through adaptor molecules. Mecha- 
nisms regulating dissociation of STATS from receptors, 
subsequent formation of homo- and heterodimers, and 
association with additional proteinsare poorly understood. 
Another important area for future investigation is delinea- 
tion of mechanisms of transcriptional activation (or repres- 
sion) by STATS after binding to the appropriate gene pro- 
moters. 
Differential and unique cellular transcriptional re- 
sponses to cytokines can only be partially explained on 
the basis of selective STAT activation. This is especially 
true in the case of cytokines, which activate the same 
STATS but elicit different cellular responses. Emerging 
evidence suggests that additional levels of regulation and 
specificity may be achieved through crosstalk of the Jak- 
STAT pathway with other major cellular signaling path- 
ways. Promising areas for future investigation include 
modification of STATS, in addition to tyrosine phosphoryla- 
tion, regulation of STATS by noncytokine ligands, mecha- 
nisms of negative regulation of STAT activity, and regula- 
tion of STATS during complex processes characterized by 
multiple interacting cell populations and cytokines, such 
as immune responses. 
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